Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alcon Research
Age
0–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of glaucoma or ocular hypertension in at least 1 eye.
Parent/legal guardian must provide informed consent, and children must agree to sign an approved assent form when applicable.
Must agree to comply with the requirements of the study and must be accompanied by a parent/guardian.
You may not be if
Females of childbearing potential that are currently pregnant, have a positive result on a pregnancy test at the Screening Visit, intend to become pregnant during the study period, are breast feeding, or are not using birth control measures.
One sighted eye or monocular, including patients who cannot be dosed in both eyes for any reason.
History of chronic, recurrent or severe inflammatory eye disease.
Ocular trauma requiring medical attention within the past 3 months prior to the Screening Visit.
Ocular infection or ocular inflammation within the past 30 days prior to the Screening Visit.
Clinically significant or progressive retinal disease such as retinal degeneration, diabetic retinopathy, or retinal detachment.
Other severe ocular pathology (including severe dry eye), that in the opinion of the Investigator, would preclude the administration of a topical prostaglandin analogue.
Intraocular surgery within the past 30 days prior to the Screening Visit.
Any abnormality preventing reliable tonometry.
Any other conditions including severe illness which would make the patient, in the opinion of the Investigator, unsuitable for the study.
Hypersensitivity to prostaglandin analogues or to any component of the study medications in the opinion of the Investigator.
Therapy with another investigational agent or device within 30 days prior to the Screening Visit.
